XML 19 R21.htm IDEA: XBRL DOCUMENT v3.19.3

Revenue

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

REVENUE

13. REVENUE

Generally, our products are promoted to veterinarians and dairy and beef producers by our sales team and then sold through distributors. Our primary market is North America. We do sell into select international regions and may expand this international reach in the future. There were no material changes between the allocation and timing of revenue recognition during the year ended December 31, 2018 or the nine-month periods ended September 30, 2019 or 2018 (under ASC 606). We do not have any contract assets such as contracts for which we have satisfied the performance obligations but do not yet have the right to bill for or contract liabilities such as customer advances. All trade receivables on our balance sheet are from contracts with customers. We incur no material costs to obtain contracts. As of March 31, 2018, we had a backlog of orders (representing purchase orders received from customers which were not fulfilled or paid) worth approximately $1,245,000 for the First Defense^® product line. Before June 30, 2018 we cleared all of this backlog (approximately $901,000) that was related to orders for Dual-Force First Defense^®.

The following table presents our product sales disaggregated by geographic area:

		During the Three-Month Periods Ended September 30,								During the Nine-Month Periods Ended September 30,
		2019				2018				2019				2018
United States		$	2,728,368			$	1,893,483			$	9,033,592			$	7,033,232
Other			242,128				260,267				1,057,385				1,016,249
Total product sales		$	2,970,496			$	2,153,750			$	10,090,977			$	8,049,481

The following table presents our product sales disaggregated by major product category:

		During the Three-Month Periods Ended September 30,								During the Nine-Month Periods Ended September 30,
		2019				2018				2019				2018
First Defense® product line		$	2,873,732			$	2,118,655			$	9,687,181			$	7,783,006
Other animal health			96,764				35,095				270,195				266,475
Other			—				—				133,601				—
Total product sales		$	2,970,496			$	2,153,750			$	10,090,977			$	8,049,481

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration